aggressive NK cell leukemia
Conditions
Interventions
study group:ruxolitinib 10mg bid D1-21
pegaspargase 2500 IU/m2 D2
gemcitabine 1000mg/m2 D1,D8
oxaliplatin 130mg/m2 D1
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. According to the fifth edition of WHO Classification of lymphohematopoietic tumors, the patient was pathologically diagnosed as aggressive NK cell leukemia (ANKL). 2. 18-80 years old; 3. No systemic anti-lymphoma therapy; 4. Women of childbearing age must be confirmed not to be pregnant through pregnancy tests, and are willing to take effective contraceptive measures during the test period and =12 months after the last dose of medication; Pregnant and lactating women cannot participate; All male subjects used contraception during the study period and =3 months after the last dose; 5. Can provide informed consent, can understand and comply with the requirements of the study.
Exclusion criteria
Exclusion criteria: 1. Severe mental illness 2.HIV infection 3. Severe renal dysfunction (glomerular filtration rate 20) 5. Known history of other active neoplasm 6. Pregnant or nursing women 7. Inability to understand or follow the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall response rate;complete remission rate;Progression-free survival; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed